Bruker Corporation (BRKR) 10-Year Financial Performance & Capital Metrics

BRKR • • Industrial / General

HealthcareMedical DevicesDiagnostic & Imaging EquipmentMedical Imaging Systems

AboutBruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.Show more

Revenue $3.37B +13.6%
EBITDA $437M -20.8%
Net Income $113M -73.5%
EPS (Diluted) 0.76 -73.8%
Gross Margin 49% -4.0%
EBITDA Margin 12.98% -30.3%
Operating Margin 7.52% -49.0%
Net Margin 3.36% -76.7%
ROE 7.01% -79.1%
ROIC 6.14% -61.9%
Debt/Equity 1.24 +26.7%
Interest Coverage 5.28 -80.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Excellent 3Y average ROE of 22.4%
✓Momentum leader: RS Rating 84 (top 16%)
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 10.2%

✗Weaknesses

✗Profits declining 10.5% over 5 years
✗Weak Piotroski F-Score: 3/9

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y6.41%

5Y10.19%

3Y11.66%

TTM6.1%

Profit (Net Income) CAGR

10Y7.15%

5Y-10.52%

3Y-25.82%

TTM-106.85%

EPS CAGR

10Y8.7%

5Y-9.62%

3Y-25.12%

TTM-107.75%

ROCE

10Y Avg14.22%

5Y Avg13.17%

3Y Avg12.63%

Latest6.68%

Peer Comparison

Medical Imaging Systems

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
IRMDIRadimed Corporation	1.3B	102.57	68.38	11.71%	26.31%	21.54%	1.35%	0.00
BRKRBruker Corporation	7.52B	49.46	65.08	13.56%	-0.61%	-0.84%	1.81%	1.24
STESTERIS plc	26.33B	268.26	43.27	6.24%	12.07%	9.8%	2.95%	0.33
FONRFONAR Corporation	114.98M	18.64	15.15	1.43%	7.08%	4.62%	6.48%	0.24
HYPRHyperfine, Inc.	100.18M	1.22	-2.18	16.84%	-378.17%	-149.05%		0.01
PACBPacific Biosciences of California, Inc.	709.48M	2.35	-2.20	-23.19%	-325.8%	-13.95%		1.33
IRIXIRIDEX Corporation	23.21M	1.35	-2.50	-6.17%	-10.04%	-108.67%		2.21
MASS908 Devices Inc.	199.79M	5.52	-2.60	18.72%	-7.17%	-3.03%		0.06

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.62B	1.61B	1.77B	1.9B	2.07B	1.99B	2.42B	2.53B	2.96B	3.37B
Revenue Growth %	-0.1%	-0.01%	0.1%	0.07%	0.09%	-0.04%	0.22%	0.05%	0.17%	0.14%
Cost of Goods Sold+	915.2M	868.8M	952.9M	995.6M	1.08B	1.05B	1.21B	1.23B	1.45B	1.72B
COGS % of Revenue	0.56%	0.54%	0.54%	0.53%	0.52%	0.53%	0.5%	0.48%	0.49%	0.51%
Gross Profit+	708.6M	742.5M	813M	900M	995.3M	939.8M	1.21B	1.31B	1.51B	1.65B
Gross Margin %	0.44%	0.46%	0.46%	0.47%	0.48%	0.47%	0.5%	0.52%	0.51%	0.49%
Gross Profit Growth %	-0.07%	0.05%	0.09%	0.11%	0.11%	-0.06%	0.29%	0.08%	0.16%	0.09%
Operating Expenses+	537.9M	539.5M	578.6M	618.1M	694.4M	691.5M	796.3M	873M	1.08B	1.4B
OpEx % of Revenue	0.33%	0.33%	0.33%	0.33%	0.34%	0.35%	0.33%	0.34%	0.36%	0.41%
Selling, General & Admin	392.2M	390.5M	415.9M	444.7M	504.8M	477.8M	562.3M	607.4M	729.4M	893.8M
SG&A % of Revenue	0.24%	0.24%	0.24%	0.23%	0.24%	0.24%	0.23%	0.24%	0.25%	0.27%
Research & Development	145.7M	149M	162.7M	173.4M	187.7M	198M	220.8M	235.9M	294.8M	376.5M
R&D % of Revenue	0.09%	0.09%	0.09%	0.09%	0.09%	0.1%	0.09%	0.09%	0.1%	0.11%
Other Operating Expenses	0	0	0	0	1.9M	15.7M	13.2M	29.7M	52.2M	126.1M
Operating Income+	145.7M	177.2M	214.7M	262.4M	300.9M	248.3M	413.3M	432.7M	436.9M	253.1M
Operating Margin %	0.09%	0.11%	0.12%	0.14%	0.15%	0.12%	0.17%	0.17%	0.15%	0.08%
Operating Income Growth %	0.38%	0.22%	0.21%	0.22%	0.15%	-0.17%	0.66%	0.05%	0.01%	-0.42%
EBITDA+	199M	231.5M	278.6M	327.3M	376.5M	328.7M	502.5M	521.4M	551.8M	436.9M
EBITDA Margin %	0.12%	0.14%	0.16%	0.17%	0.18%	0.17%	0.21%	0.21%	0.19%	0.13%
EBITDA Growth %	0.21%	0.16%	0.2%	0.17%	0.15%	-0.13%	0.53%	0.04%	0.06%	-0.21%
D&A (Non-Cash Add-back)	53.3M	54.3M	63.9M	64.9M	75.6M	80.4M	89.2M	88.7M	114.9M	183.8M
EBIT	182.6M	207.8M	235.6M	275.2M	296.4M	240.2M	407.9M	430M	560.6M	254.8M
Net Interest Income+	-11.8M	-12.9M	-14.6M	-11.4M	-14.7M	-11.2M	-13.4M	-13.3M	-8.9M	-38.6M
Interest Income	1.2M	300K	800K	1.2M	1.3M	3.2M	900K	2.8M	7.5M	9.3M
Interest Expense	13M	13.2M	15.4M	12.6M	16M	14.4M	14.3M	16.1M	16.4M	47.9M
Other Income/Expense	-17.7M	-4.2M	-21.7M	-17.7M	-20.5M	-22.5M	-19.7M	-17.8M	109.3M	-47.9M
Pretax Income+	128M	177.6M	197.8M	244.7M	280.4M	225.8M	393.6M	414.9M	546.2M	205.2M
Pretax Margin %	0.08%	0.11%	0.11%	0.13%	0.14%	0.11%	0.16%	0.16%	0.18%	0.06%
Income Tax+	23.1M	23.1M	117.5M	63.7M	82.4M	64.4M	113M	116.4M	117.7M	91.4M
Effective Tax Rate %	0.79%	0.86%	0.4%	0.73%	0.7%	0.7%	0.7%	0.71%	0.78%	0.55%
Net Income+	101.6M	153.6M	78.6M	179.7M	197.2M	157.8M	277.1M	296.6M	427.2M	113.1M
Net Margin %	0.06%	0.1%	0.04%	0.09%	0.1%	0.08%	0.11%	0.12%	0.14%	0.03%
Net Income Growth %	0.79%	0.51%	-0.49%	1.29%	0.1%	-0.2%	0.76%	0.07%	0.44%	-0.74%
Net Income (Continuing)	104.9M	154.5M	80.3M	181M	198M	161.4M	280.6M	298.5M	428.5M	113.8M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	6.8M	6.7M	8.1M	8.5M	31.4M	13.1M	14.3M	18M	36.1M	34M
EPS (Diluted)+	0.60	0.95	0.49	1.14	1.26	1.02	1.81	1.99	2.90	0.76
EPS Growth %	0.82%	0.58%	-0.48%	1.33%	0.11%	-0.19%	0.77%	0.1%	0.46%	-0.74%
EPS (Basic)	0.60	0.95	0.50	1.15	1.27	1.03	1.83	2.00	2.92	0.76
Diluted Shares Outstanding	169.1M	162.2M	159.1M	157.2M	156.6M	154.6M	152.9M	149.4M	147.2M	149.5M
Basic Shares Outstanding	168.2M	161.4M	158.1M	156.2M	155.2M	153.4M	151.4M	148.6M	146.4M	149M
Dividend Payout Ratio	-	0.17%	0.32%	0.14%	0.13%	0.16%	0.09%	0.1%	0.07%	0.27%

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.23B	1.27B	1.36B	1.3B	1.8B	1.93B	2.47B	2.11B	2.16B	2.05B
Cash & Short-Term Investments	468.3M	500.3M	439.2M	322.4M	684.9M	731.8M	1.17B	645.5M	488.3M	183.4M
Cash Only	267.1M	342.4M	325M	322.4M	678.3M	681.8M	1.07B	645.5M	488.3M	183.4M
Short-Term Investments	201.2M	157.9M	114.2M	0	6.6M	50M	100M	0	0	0
Accounts Receivable	234.7M	243.9M	319.3M	357.2M	362.2M	335.3M	416.9M	595.3M	621.8M	701.2M
Days Sales Outstanding	52.76	55.25	66	68.78	63.79	61.58	62.93	85.86	76.56	76.03
Inventory	422M	440.4M	486.2M	509.6M	577.2M	692.3M	710.1M	800.1M	968.3M	1.07B
Days Inventory Outstanding	168.3	185.02	186.23	186.83	195.56	241.19	214.51	238.4	243.54	227.01
Other Current Assets	106.5M	91.3M	114.1M	115.1M	172M	165.6M	176.6M	29M	30.3M	39.6M
Total Non-Current Assets+	499.3M	540.1M	589.7M	824.3M	975.2M	1.12B	1.18B	1.5B	2.09B	3.75B
Property, Plant & Equipment	231.1M	239.1M	266.5M	270.6M	371.7M	462.9M	466M	538.2M	691.4M	814.8M
Fixed Asset Turnover	7.03x	6.74x	6.63x	7.01x	5.58x	4.29x	5.19x	4.70x	4.29x	4.13x
Goodwill	130.6M	130.6M	169.8M	275.7M	293M	320.4M	339.5M	457.6M	582.6M	1.51B
Intangible Assets	74.7M	69.7M	82.4M	218.7M	233.2M	229.1M	211.8M	270.9M	330.5M	912.5M
Long-Term Investments	-62.9M	-93.1M	-71M	-59.3M	0	0	0	0	0	0
Other Non-Current Assets	9.9M	16.6M	14M	8.4M	16.8M	39.6M	70.8M	155.1M	184M	232.7M
Total Assets+	1.73B	1.81B	1.95B	2.13B	2.77B	3.05B	3.65B	3.61B	4.25B	5.81B
Asset Turnover	0.94x	0.89x	0.91x	0.89x	0.75x	0.65x	0.66x	0.70x	0.70x	0.58x
Asset Growth %	-0.07%	0.05%	0.07%	0.09%	0.3%	0.1%	0.2%	-0.01%	0.18%	0.37%
Total Current Liabilities+	554.6M	525.9M	524.5M	598M	645.6M	791.9M	938.5M	914.3M	1.2B	1.28B
Accounts Payable	72.1M	86.1M	90.8M	104.5M	118.4M	134.6M	147.4M	178.4M	202.7M	234.1M
Days Payables Outstanding	28.75	36.17	34.78	38.31	40.12	46.89	44.53	53.16	50.98	49.77
Short-Term Debt	600K	20.1M	0	18.5M	500K	2.2M	112.4M	18.7M	121.2M	32.5M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	306.8M	269.8M	256.3M	288.5M	119.5M	121.3M	156.4M	159.9M	218.3M	300.3M
Current Ratio	2.22x	2.42x	2.59x	2.18x	2.78x	2.43x	2.63x	2.31x	1.80x	1.60x
Quick Ratio	1.46x	1.58x	1.66x	1.33x	1.89x	1.56x	1.88x	1.44x	0.99x	0.77x
Cash Conversion Cycle	192.3	204.1	217.45	217.29	219.23	255.87	232.91	271.1	269.12	253.27
Total Non-Current Liabilities+	443.4M	593.9M	690.5M	625.5M	1.19B	1.28B	1.63B	1.57B	1.63B	2.71B
Long-Term Debt	265.2M	391.6M	415.6M	322.6M	812.8M	842.3M	1.22B	1.2B	1.16B	2.06B
Capital Lease Obligations	0	0	1.3M	7.1M	47M	47M	41.8M	34.8M	74.8M	118.9M
Deferred Tax Liabilities	9.5M	10.1M	24.3M	51.1M	48.8M	43.1M	46M	62.3M	67.7M	118.5M
Other Non-Current Liabilities	123.5M	145.4M	200.6M	182.5M	236.3M	299.5M	266.9M	166.5M	240.2M	311M
Total Liabilities	998M	1.12B	1.22B	1.22B	1.83B	2.07B	2.57B	2.48B	2.84B	3.99B
Total Debt+	266.7M	411.7M	415.6M	341.1M	880.9M	912.8M	1.39B	1.27B	1.38B	2.25B
Net Debt	-400K	69.3M	90.6M	18.7M	202.6M	231M	325.7M	624.9M	891.3M	2.06B
Debt / Equity	0.36x	0.59x	0.56x	0.37x	0.94x	0.94x	1.28x	1.12x	0.98x	1.24x
Debt / EBITDA	1.34x	1.78x	1.49x	1.04x	2.34x	2.78x	2.77x	2.44x	2.50x	5.14x
Net Debt / EBITDA	-0.00x	0.30x	0.33x	0.06x	0.54x	0.70x	0.65x	1.20x	1.62x	4.72x
Interest Coverage	11.21x	13.42x	13.94x	20.83x	18.81x	17.24x	28.90x	26.88x	26.64x	5.28x
Total Equity+	739.7M	699.8M	741.6M	913.6M	938.2M	974.3M	1.08B	1.13B	1.41B	1.82B
Equity Growth %	-0.05%	-0.05%	0.06%	0.23%	0.03%	0.04%	0.11%	0.04%	0.25%	0.28%
Book Value per Share	4.37	4.31	4.66	5.81	5.99	6.30	7.09	7.58	9.60	12.14
Total Shareholders' Equity	732.9M	693.1M	733.5M	905.1M	906.8M	961.2M	1.07B	1.11B	1.38B	1.78B
Common Stock	1.7M	1.7M	1.7M	1.7M	1.7M	1.7M	1.7M	1.7M	1.7M	1.8M
Retained Earnings	757.4M	885.2M	942M	1.1B	1.27B	1.41B	1.66B	1.93B	2.32B	2.41B
Treasury Stock	-90.9M	-249.3M	-401.2M	-401.5M	-543.8M	-667M	-820.3M	-1.08B	-1.24B	-1.24B
Accumulated OCI	-44.2M	-75.9M	27M	17M	-25.5M	3.7M	-8.2M	14.8M	6M	-103.5M
Minority Interest	6.8M	6.7M	8.1M	8.5M	31.4M	13.1M	14.3M	18M	36.1M	34M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	229.2M	130.8M	154.4M	239.7M	213.4M	332.2M	282.4M	274.4M	350.1M	251.3M
Operating CF Margin %	0.14%	0.08%	0.09%	0.13%	0.1%	0.17%	0.12%	0.11%	0.12%	0.07%
Operating CF Growth %	1.01%	-0.43%	0.18%	0.55%	-0.11%	0.56%	-0.15%	-0.03%	0.28%	-0.28%
Net Income	104.9M	154.5M	80.3M	181M	198M	161.4M	280.6M	298.5M	427.2M	113.8M
Depreciation & Amortization	53.3M	54.3M	63.9M	64.9M	75.6M	80.5M	89.1M	88.7M	114.9M	183.8M
Stock-Based Compensation	8M	9.4M	11M	11.3M	9.6M	16M	17.2M	27.7M	24M	25.3M
Deferred Taxes	-29.4M	-26.9M	28.2M	-15.1M	-5.4M	-22.5M	-5.8M	-14.8M	-24.4M	-63.8M
Other Non-Cash Items	46.1M	24.1M	11.6M	39.8M	10.1M	27.2M	26.5M	18.4M	-103.8M	70.4M
Working Capital Changes	46.3M	-84.6M	-40.6M	-42.2M	-74.5M	69.6M	-125.2M	-144.1M	-87.8M	-78.2M
Change in Receivables	45M	-8.4M	-55.5M	-30.5M	-5M	40.8M	-95.3M	-67.9M	-900K	-40.6M
Change in Inventory	-5.4M	-43.2M	-6.6M	-35.5M	-60.2M	-91.6M	-67M	-137.9M	-125M	-69.8M
Change in Payables	12.6M	-19.6M	33.7M	6.2M	15.9M	-2.4M	61.8M	33.3M	23.1M	20.8M
Cash from Investing+	-102.4M	-21.8M	-30.2M	-123.4M	-158.4M	-192.7M	-192.4M	-251.6M	-326M	-1.76B
Capital Expenditures	-34.2M	-37.1M	-43.7M	-49.2M	-73M	-97.2M	-92M	-129.2M	-106.9M	-115.3M
CapEx % of Revenue	0.02%	0.02%	0.02%	0.03%	0.04%	0.05%	0.04%	0.05%	0.04%	0.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	900K	1.1M	11.5M	118.9M	11M	200K	4.9M	13.9M	11.1M	1.1M
Cash from Financing+	-168M	-27.2M	-159M	-112.4M	300M	-161.6M	318.7M	-415.3M	-193.4M	1.23B
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	-25.8M	-25.4M	-25.1M	-25M	-24.6M	-24.2M	-29.8M	-29.4M	-30.2M
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	10.1M	12.7M	15.5M	-3.2M	-10.6M	-8.8M	-500K	-11.7M	300K	-18.9M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	195M	93.7M	110.7M	190.5M	140.4M	235M	190.4M	145.2M	243.2M	136M
FCF Margin %	0.12%	0.06%	0.06%	0.1%	0.07%	0.12%	0.08%	0.06%	0.08%	0.04%
FCF Growth %	1.42%	-0.52%	0.18%	0.72%	-0.26%	0.67%	-0.19%	-0.24%	0.67%	-0.44%
FCF per Share	1.15	0.58	0.70	1.21	0.90	1.52	1.25	0.97	1.65	0.91
FCF Conversion (FCF/Net Income)	2.26x	0.85x	1.96x	1.33x	1.08x	2.11x	1.02x	0.93x	0.82x	2.22x
Interest Paid	12.2M	12.5M	15.2M	11.7M	16M	28.7M	19.6M	24.3M	33.7M	54.6M
Taxes Paid	56.6M	72.4M	53.1M	60.5M	61.3M	43M	145.5M	147.4M	96.6M	153.9M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	13.39%	21.34%	10.91%	21.71%	21.3%	16.5%	26.91%	26.76%	33.57%	7.01%
Return on Invested Capital (ROIC)	14.08%	17.62%	20.11%	22.31%	21.77%	15.88%	23.7%	20.49%	16.14%	6.14%
Gross Margin	43.64%	46.08%	46.04%	47.48%	48.02%	47.29%	50.03%	51.59%	51.05%	49%
Net Margin	6.26%	9.53%	4.45%	9.48%	9.51%	7.94%	11.46%	11.72%	14.41%	3.36%
Debt / Equity	0.36x	0.59x	0.56x	0.37x	0.94x	0.94x	1.28x	1.12x	0.98x	1.24x
Interest Coverage	11.21x	13.42x	13.94x	20.83x	18.81x	17.24x	28.90x	26.88x	26.64x	5.28x
FCF Conversion	2.26x	0.85x	1.96x	1.33x	1.08x	2.11x	1.02x	0.93x	0.82x	2.22x
Revenue Growth	-10.23%	-0.77%	9.59%	7.34%	9.34%	-4.11%	21.66%	4.67%	17.14%	13.56%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Product	-	-	-	1.58B	1.74B	1.64B	2.02B	2.11B	2.46B	2.76B
Product Growth	-	-	-	-	10.66%	-6.11%	23.15%	4.59%	16.48%	12.27%
Product and Service, Other	-	-	-	-	-	-	7.4M	6.2M	13.1M	607.2M
Product and Service, Other Growth	-	-	-	-	-	-	-	-16.22%	111.29%	4535.11%
Service	-	-	-	311.7M	322.4M	343.4M	393.2M	414.6M	493.8M	-
Service Growth	-	-	-	-	3.43%	6.51%	14.50%	5.44%	19.10%	-
Product And Service Other	-	-	-	7.3M	5.5M	6M	-	-	-	-
Product And Service Other Growth	-	-	-	-	-24.66%	9.09%	-	-	-	-
Scientific Instruments	1.5B	1.49B	1.58B	-	-	-	-	-	-	-
Scientific Instruments Growth	-	-0.44%	6.12%	-	-	-	-	-	-	-
Energy And Supercon Technologies	133.7M	130.2M	191.2M	-	-	-	-	-	-	-
Energy And Supercon Technologies Growth	-	-2.62%	46.85%	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	-	-	-	-	-	-	601M	696.1M	777.7M	938.5M
UNITED STATES Growth	-	-	-	-	-	-	-	15.82%	11.72%	20.68%
Rest Of Europe	479.6M	393.4M	465M	500.2M	505.2M	519.8M	658.1M	591.9M	699.7M	873M
Rest Of Europe Growth	-	-17.97%	18.20%	7.57%	1.00%	2.89%	26.61%	-10.06%	18.21%	24.77%
Asia Pacific	-	-	-	-	-	-	-	-	-	518.5M
Asia Pacific Growth	-	-	-	-	-	-	-	-	-	-
CHINA	-	-	-	-	-	-	-	396.5M	528.1M	471.2M
CHINA Growth	-	-	-	-	-	-	-	-	33.19%	-10.77%
GERMANY	-	-	-	-	-	-	-	247.4M	281.5M	310.7M
GERMANY Growth	-	-	-	-	-	-	-	-	13.78%	10.37%
Other Country	150M	142.1M	151.2M	155.7M	173M	137.8M	167.1M	190.4M	216.6M	254.5M
Other Country Growth	-	-5.27%	6.40%	2.98%	11.11%	-20.35%	21.26%	13.94%	13.76%	17.50%
Asia Pacific	414.9M	458.1M	514.8M	549.2M	651M	629.1M	729.1M	408.4M	460.9M	-
Asia Pacific Growth	-	10.41%	12.38%	6.68%	18.54%	-3.36%	15.90%	-43.99%	12.86%	-
DELAWARE	-	-	-	-	-	-	262.6M	-	-	-
DELAWARE Growth	-	-	-	-	-	-	-	-	-	-
U	380.4M	428.2M	434.7M	489.4M	529.8M	455.9M	-	-	-	-
U Growth	-	12.57%	1.52%	12.58%	8.26%	-13.95%	-	-	-	-
D	198.9M	189.5M	200.2M	201.1M	213.6M	244.9M	-	-	-	-
D Growth	-	-4.73%	5.65%	0.45%	6.22%	14.65%	-	-	-	-

Frequently Asked Questions

Valuation & Price

Bruker Corporation (BRKR) has a price-to-earnings (P/E) ratio of 65.1x. This suggests investors expect higher future growth.

Growth & Financials

Bruker Corporation (BRKR) reported $3.44B in revenue for fiscal year 2024. This represents a 108% increase from $1.65B in 2011.

Bruker Corporation (BRKR) grew revenue by 13.6% over the past year. This is steady growth.

Bruker Corporation (BRKR) reported a net loss of $20.9M for fiscal year 2024.

Dividend & Returns

Yes, Bruker Corporation (BRKR) pays a dividend with a yield of 0.41%. This makes it attractive for income-focused investors.

Bruker Corporation (BRKR) has a return on equity (ROE) of 7.0%. This is below average, suggesting room for improvement.

Bruker Corporation (BRKR) had negative free cash flow of $10.6M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...